Pharmaceuticals
US Anti-Depressants Drugs Market Analysis
The US Anti-depressant drugs market size was valued at $6.9 billion in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 3.9% from 2022 to 2030 and will reach $9.37 billion in 2030. The market is segmented by drug class, indication, route of administration, end-user, and distribution channel. The US Anti-depressant drug market will grow because of the development of novel antidepressant drugs and the expansion of the product portfolio of pharmaceutical companies. The key market players are Eli Lilly and Company (USA), Pfizer Inc. (USA), Bristol-Myers Squibb (USA), and others.
Buy Now
US Anti-Depressants Drugs Market Executive Summary
The US Anti-Depressants drugs market size was valued at $6.9 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 3.9% from 2022 to 2030 and will reach $9.37 Bn in 2030. Mental health expenditure in US is significant due to the high prevalence of mental health disorders, including depression, anxiety, and substance use disorders. According to a report by the National Institute of Mental Health (NIMH), mental health and substance use disorder services accounted for an estimated $220 BN in healthcare spending in the United States in 2019. In US, mental health expenditures are divided between public and private spending. In the United States, public spending accounted for approximately 34% of mental health expenditures, with private insurance accounting for 43% and out-of-pocket expenses accounting for 23%.
Depression is a common mental health disorder in US, affecting millions of people each year. According to the World Health Organization (WHO), depression is the leading cause of disability in US, with an estimated 19 Mn people affected by the disorder each year. In the US, the National Institute of Mental Health (NIMH) reports that an estimated 17.3 Mn adults (or 7.1% of the population) experienced at least one major depressive episode in 2017. The NIMH reports that the highest rates of depression are among adults aged 18-25 years old. The high prevalence of depression in US has a significant impact on the antidepressant drugs market in the region. Here are some key factors that contribute to the impact of depression prevalence on the antidepressant drugs market in US. The high prevalence of depression in US creates a large market for antidepressant drugs. The high prevalence of depression in US also leads to a high rate of treatment for the disorder, including the use of antidepressant drugs. According to the National Center for Health Statistics, over 12% of adults in the United States took an antidepressant medication in 2017-2018.
The high demand for antidepressant drugs in US has led to a competitive market for these medications. There are many different types of antidepressant drugs available on the market, including selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants. This competition helps to drive innovation and development in the field of antidepressant drugs. The rising need for antidepressant drugs also affects pricing in the market. Many antidepressant drugs are available in generic forms, which can help to make them more affordable for patients.
Market Dynamics
Market Growth Drivers Analysis
The market for antidepressants is mainly driven by the rising incidence of depression and other mental health conditions in the US. Almost 264 million people in the US alone suffer from depression, which is a primary cause of disability globally, according to the World Health Organization (WHO). Therefore, there is a rising need for efficient depression management therapies, such as antidepressant medications. Growth in the market is also being fueled by increasing public awareness of mental health problems and the availability of efficient treatments.
The creation of brand-new antidepressants and the extension of pharmaceutical companies' product lines are also contributing to the market's expansion. The market is anticipated to experience new growth prospects as a result of rising research & development spending, the introduction of customised medicine, and the expanding popularity of combination medicines.
Market Restraints
There are various market constraints as well, and one of them is the proliferation of generic antidepressant medications. Since generic medications are less expensive than branded ones, the market's overall revenue may be affected. Moreover, antidepressant side effects like weight gain, nausea, and dizziness may make it harder for patients to comply with treatment and stick with it.
The strict regulatory standards for antidepressant drug approval can potentially be a barrier to the market's expansion. The approval and introduction of new antidepressant medications may be delayed due to lengthy and complicated clinical trials, expensive development costs, and rising regulatory scrutiny.
Competitive Landscape
Key Players
- Pfizer Inc. (USA)
- Bristol-Myers Squibb (USA)
- Eli Lilly and Company (USA)
- Mylan N.V. (USA.)
- Amneal Pharmaceutical Inc (USA)
- Avet Pharmaceuticals Inc. (USA)
- Johnson & Johnson
- Allergan (now part of AbbVie Inc.)
- GlaxoSmithKline plc
- Apotex Inc.
- Bausch Health Companies Inc.
- Lundbeck
- Merck & Co., Inc.
- AbbVie Inc.
- Mylan N.V.
- Novartis AG
Recent developments
March 2021: The FDA approved a new indication for the drug, Vraylar (cariprazine), which is marketed by Allergan (now part of AbbVie Inc.). Vraylar is now approved for the treatment of depressive episodes associated with bipolar I disorder in adults.
January 2021: Janssen Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved its drug, Spravato (esketamine), for the treatment of depressive symptoms in adults with the major depressive disorder who have not responded to other treatments. This approval marked an important development in the field of depression treatment, as Spravato is the first medication in decades to use a new mechanism of action for treating depression.
Healthcare Policies and Regulatory Landscape
Regulations for the approval, marketing, and pricing of antidepressant drugs in US are overseen by various government agencies. In the United States, the Food and Drug Administration (FDA) regulates the approval of antidepressant drugs. To gain approval, a drug manufacturer must demonstrate that the drug is safe and effective for its intended use through a rigorous process of clinical trials.
Antidepressant drug manufacturers in US are subject to regulations around marketing their products. In the United States, the FDA regulates the advertising and promotion of prescription drugs, including antidepressants, to ensure that the information provided to consumers is accurate and not misleading.
Pricing for antidepressant drugs in US can vary depending on a number of factors, including the specific drug, insurance coverage, and geographic location. In the United States, the price of prescription drugs, including antidepressants, is largely driven by market competition, as well as negotiations between pharmaceutical companies and insurance providers
In terms of access to antidepressant drugs, the US have programs in place to help make medications more affordable for those who need them. In the US, programs like Medicare and Medicaid can provide coverage for antidepressant drugs for eligible individuals.
Reimbursement scenario
In the US, coverage for antidepressant drugs is largely driven by private insurance plans and government programs like Medicare and Medicaid. Most private insurance plans in the US cover prescription drugs, including antidepressants, although coverage can vary depending on the specific plan. Medicare Part D, which provides prescription drug coverage for older adults and people with certain disabilities, also covers antidepressants.
Medicaid, which provides health coverage for low-income individuals and families, covers antidepressants as well as other mental health medications. Eligibility and coverage for Medicaid vary by state, but all states are required to cover certain mental health services, including prescription drugs.
In addition, the Affordable Care Act (ACA) requires most health insurance plans to cover mental health and substance use disorder services, including prescription drugs like antidepressants. This means that most private insurance plans in the United States are required to cover antidepressant drugs, although cost-sharing requirements and formulary restrictions may still apply.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
US Anti-Depressants Drugs Market Segmentation
Drug Class
The market is divided into monoamine oxidase inhibitors, atypical antidepressants, tricyclic, serotonin, and norepinephrine reuptake inhibitors, selective serotonin reuptake inhibitors, and others based on pharmacological class. In 2021, the selective serotonin reuptake inhibitors (SSRIs) market segment held the biggest market share. The strength of the pipeline of top players to assess new potential candidates in this drug class, combined with the clinical advantage of SSRIs over conventional medications in the management and treatment of depression, is anticipated to accelerate the segment's growth.
- Tricyclic Antidepressants (TCAs) - Amitriptyline (Elavil), Amoxapine (Asendin), Desipramine (Norpramin), Doxepin (Silenor), Imipramine (Tofranil), Nortriptyline (Pamelor), Protriptyline (Vivactil), Trimipramine (Surmontil)
- Selective Serotonin Reuptake Inhibitors (SSRIs) - Citalopram (Cipramil), Dapoxetine (Priligy), Escitalopram (Cipralex), Fluoxetine (Prozac or Oxactin), Fluvoxamine (Faverin), Paroxetine (Seroxat), Sertraline (Lustral), Vortioxetine (Brintellix)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) - Desvenlafaxine (Pristiq), Duloxetine (Cymbalta), Levomilnacipran (Fetzima), Venlafaxine (Effexor XR)
- Monoamine Oxidase Inhibitors (MAOIs) - Socarboxazid (Marplan), Phenelzine (Nardil), Selegiline (Emsam), Tranylcypromine (Parnate)
- Serotonin Antagonist and Reuptake Inhibitors (SARI) - Etoperidone (Axiomin, Etonin), Lorpiprazole (Normarex), Mepiprazole (Psigodal), Nefazodone (Serzone, Nefadar), Trazodone (Desyrel)
- Others
Indication
By Indication, the major depressive disorder segment was the major contributor in 2021 and is expected to maintain its lead during the forecast period, owing to an increase in the prevalence of major depressive disorder and initiatives taken by governments and private organizations about the development of drugs. However, the obsessive-compulsive disorder segment is expected to witness considerable growth during the forecast period, owing to an increase in the prevalence of mental disorders and an increase in the number of approval for anxiety drugs.
- Major Depressive Disorder
- Anxiety Disorders
- Attention Deficit Hyperactivity Disorder
- Others
Route of Administration
Based on the route of administration the market is segmented into:
- Oral
- Injectable
- Others
End-Users
Based on end users the market is segmented into:
- Hospitals
- Homecare
- Speciality Centres
- Others
Distribution Channel
Hospital pharmacies, retail pharmacies, and online pharmacies are the three types of pharmacies that make up the market based on the distribution channel. In 2019, the hospital pharmacies segment dominated the world market. Nonetheless, the expansion of the retail pharmacy market might be attributed to patients' increasing demand for these establishments. Due to the growing prevalence of online pharmacies in emerging countries, the segment of online pharmacies is estimated to see a profitable CAGR over the forecast timeframe.
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Insights10 will provide you with the reports within 10 key parameters which are:
- Market Overview
- Market Growth Drivers & Restraints
- Epidemiology of Disease Type
- Market Segmentation
- Market Share
- Competitive Landscape
- Key Company Profiles
- Healthcare Policies & Regulatory Framework
- Reimbursement Scenario
- Factors Driving Future Growth
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
(1).png)
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
- Establishing market drivers and trends
- Analyzing the regulatory landscape to understand future growth
- Market Segment based analysis to obtain revenue/volume
- Analyzing current needs and determining penetration to estimate the market
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
- Intelligent insights to take informed business decisions
- Qualitative, acute and result oriented market analysis
- Market size and forecasts from 2022 to 2030
- Opportunities for expansion and in-depth market analysis
- Segmentation and regional revenue forecasts
- Analysis of the market share and competitive landscape
- Strategic Recommendations to chart future course of action
- Comprehensive Market Research Report in PDF and PPT formats
Need more?
- Ask our analyst how this study was put together to learn more
- Discuss additional requirements as part of the free customisation
- Add more countries or regions to the scope
- Get answers to specific business questions
- Develop the business case to launch the product
- Find out how this report may influence your business revenue
Related reports (by category)
Pharmaceuticals
Belgium Infectious Disease Therapeutics Market Analysis
Pharmaceuticals
Egypt Pharmaceutical Robots Market Analysis
Pharmaceuticals
UK Glutathione Market Analysis
Related reports (by geography)
Pharmaceuticals
US Cholesterol Therapeutics Market Analysis
Clinical Trials
US Oncology Clinical Trials Market Analysis
Medical Devices
US Pain Management Devices Market Analysis
Pharmaceuticals